source
- Servier’s $1.5 billion muscular dystrophy drug sevasemten fails pivotal trialServier announced that its experimental muscular dystrophy therapy sevasemten did not meet its goals in a pivotal Phase III study. The trial, named GRAND CANYON, evaluated the drug’s ability to im…
- Ultragenyx cuts 20% of workforce and abandons Wilson disease gene therapy after mixed Q3 resultsUltragenyx said it will cut about 20% of its workforce, marking a second round of layoffs this year. The reductions will affect roughly a fifth of the company's employees. At the same time, the fi…